+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 121 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
A

Actively Recruiting

Researchers are evaluating an investigational drug called ALN-HSD for adults with Metabolic Dysfunction-Associated SteatoHepatitis MASH, a liver condition marked by fat buildup, inflammation, and scarring that can lead to cirrhosis and liver failure. This Phase 2 study aims to understand how ALN-HSD affects liver scarring and inflammation in participants who have genetic risk factors for MASH. Participants are randomly assigned in a 11 ratio to receive either ALN-HSD or a placebo. The study is double-blind and quadruple-masked, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment is administered according to the study protocol over a period of 52 weeks, with follow-up monitoring extending to 84 weeks to assess safety. During the study, participants will undergo various assessments including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and genetic evaluations. Researchers will track changes in liver fibrosis and inflammation as well as the presence of drug metabolites in blood samples. Safety is monitored throughout the study and beyond the treatment period. The total duration of participation is up to 84 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
71 locations
C

Actively Recruiting

Researchers are studying the safety and effectiveness of zenagamtide compared to semaglutide for treating adults with excess body weight. This Phase 3 trial focuses on participants with overweight or obesity to evaluate how these treatments help with weight loss. Participants are randomly assigned to one of three groups one receiving zenagamtide plus a placebo matching semaglutide, another receiving a lower dose of semaglutide plus a placebo matching zenagamtide, and the last group receiving a higher dose of semaglutide plus a placebo matching zenagamtide. All injections are given subcutaneously once weekly using pre-filled pen injectors in the thigh, abdomen, or upper arm. Participants also follow a reduced-calorie diet and increase physical activity throughout the study. During the 84-week study period, participants will be regularly monitored for changes in body weight and waist circumference. The main outcome is the relative change in body weight from the start to week 84. Safety and adherence will be assessed through scheduled visits where injections, diet, and exercise are reviewed. The study lasts until October 2028, with ongoing evaluations at specific intervals to understand treatment effects and safety.

Age: 18Years +All GendersPhase 3
45 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
C

Actively Recruiting

This trial evaluates treatments for children and young adults aged 2 to 21 with newly diagnosed or untreated low-grade glioma LGG that does not have a BRAFV600E mutation or systemic neurofibromatosis type 1. The study aims to compare the effects of selumetinib, an oral drug that blocks enzymes needed for cell growth, with the standard chemotherapy regimen of carboplatin and vincristine. The main goal is to determine if selumetinib is as effective as the standard treatment in preventing disease events and to see if it improves quality of life. Participants are randomly assigned to one of two treatment groups. One group receives vincristine and carboplatin intravenously during an induction phase followed by maintenance cycles every 42 days for up to 8 cycles. The other group takes selumetinib orally twice daily in 28-day cycles for up to 27 cycles. Both groups undergo regular blood collection and MRI scans throughout treatment. The selumetinib group also has heart function evaluated by echocardiography at the start. During the study, participants will have assessments including visual acuity tests, motor function evaluations, quality of life and cognitive function questionnaires. Follow-up visits occur every 3 months for the first year, then every 6 months for years 2 and 3, and annually thereafter up to 10 years. The primary outcome measured is event-free survival over this period. The study also collects tumor and blood samples to explore genetic factors related to treatment response.

Age: 2Years - 21YearsAll GendersPhase 3
132 locations
P

Actively Recruiting

Researchers are evaluating treatments for children and young adults with low-risk and average-risk medulloblastoma, a type of brain cancer. This phase III trial aims to test two main ideas whether adding sodium thiosulfate STS to standard chemotherapy and radiation can reduce hearing loss caused by cisplatin in average-risk patients, and whether a less intense radiation therapy can be as effective for low-risk patients while reducing side effects. The study also compares outcomes to previous treatments to ensure survival and recurrence rates are not negatively affected. Participants receive radiation therapy daily for 6 weeks and weekly vincristine during treatment weeks. Maintenance therapy begins about 4 weeks later and includes cycles of oral lomustine, intravenous cisplatin, intravenous sodium thiosulfate, cyclophosphamide, and vincristine given on specific days and cycles over several months. Patients undergo MRI scans and cerebrospinal fluid collections throughout the study, with optional blood samples. After treatment, follow-up visits occur regularly for up to 10 years. Throughout the study, participants have hearing tests, brain scans, and lab tests to monitor effects and side effects. Researchers assess hearing loss, event-free and overall survival, kidney function, neurocognitive outcomes, quality of life, and social factors. Hearing loss is evaluated shortly after treatment and over time. This long-term monitoring helps understand the safety and impact of the treatments, with total involvement lasting up to 10 years after starting therapy.

Age: 4Years - 21YearsAll GendersPhase 3
111 locations
C

Actively Recruiting

Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.

Age: 1Year - 30YearsAll GendersPhase 2
227 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations

1-10 of 121

1